Synonyms: Example 8 [WO2019182925A1] | GDC6599
Compound class:
Synthetic organic
Comment: GDC-6599 is a TRPA1 cation channel antagonist that was developed for potential to treat chronic cough associated with respiratory conditions such as asthma and COPD.
The structure of GDC-6599 was disclosed at the American Chemical Society (ACS) meeting in August 2023. It is one of the TRP antagonists claimed in Genentech/Hoffmann-La Roche patent WO2019182925A1 [1]. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Terrett JA, Chen H, Constantineau-Forget L, Larouch-Gauthier R, Lepissier L, Beumier F, Dery M, Grand-Maitre C, Sturino C, Volgraf M et al.. (2019)
Oxadiazole transient receptor potential channel inhibitors. Patent number: WO2019182925A1. Priority date: 18/03/2019. Publication date: 26/09/2019. |